Effect of Rose-colored Glass on Mood

Effect of Rose-colored Glass on Mood: A Randomized Clinical Trial

Decades of psychological research has highlighted the impact of visual perception on mood and happiness. The investigators hypothesized that literally seeing the world through rose colored glasses may have an effect on perception, mood, and happiness. After cataract surgery, which classically increases the vividness of perceived colors, patients report significant satisfaction. The investigators therefore sought to explore whether using pink colored lenses leads to a measurable impact on outcomes.

Study Overview

• Status: Completed
• Conditions: Mood
• Intervention / Treatment: Other: Wearing pink glasses; Other: Wearing clear glasses

Detailed Description

A randomized controlled clinical trial design will be performed. Subjects will be randomized for either pink lenses (treatment group) or clear lenses (placebo group).

Subjects will be asked to wear the assigned glasses throughout the day during the course of the trial. Glasses will not be work while driving at night.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Jacksonville, Florida, United States, 32204
      • St Vincent's Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects over 18 years of age.

Exclusion Criteria:

• Subjects who wear glasses on a regular basis.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pink lenses; Pink-colored lenses	Other: Wearing pink glasses; Wearing pink-colored lenses
Placebo Comparator: Clear lenses	Other: Wearing clear glasses; Wearing clear glasses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Anxiety Scores on the Visual Analogue Scale at 1 week	Scale range 0-100, higher values represent more anxiety	1 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Mood Scores on the Visual Analogue Scale	Scale range 0-100, higher values represent more sadness	1 week
Change from baseline in Happiness Scores on the Visual Analogue Scale	Scale range 0-100, higher values represent more happiness	1 week
Change from baseline in the Center for Epidemiological Studies Depression Scale score	Scale range 0-60, higher values suggest more depressive symptoms	1 week

Collaborators and Investigators

• Sponsor: Florida Center for Dermatology
• Investigators: Principal Investigator: Jonathan Kantor, MD, Florida Center for Dermatology

Study record dates

Study Major Dates

• Study Start (Actual): August 30, 2018
• Primary Completion (Actual): June 30, 2019
• Study Completion (Actual): June 30, 2019

Study Registration Dates

• First Submitted: August 14, 2018
• First Submitted That Met QC Criteria: June 18, 2019
• First Posted (Actual): June 20, 2019

Study Record Updates

• Last Update Posted (Actual): August 25, 2020
• Last Update Submitted That Met QC Criteria: August 21, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Dopamine Agents; Dopamine Uptake Inhibitors; Central Nervous System Stimulants; Sympathomimetics; Adrenergic Uptake Inhibitors; Methamphetamine
• Other Study ID Numbers: RCG101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Anonymized data are available to other researchers upon reasonable request.
• IPD Sharing Time Frame: Data are available to other researchers upon reasonable request.
• IPD Sharing Access Criteria: Data are available to other researchers upon reasonable request.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No